Clinical trial
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
NCT02413346 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
- Lead sponsor
- Almirall, S.A.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 20, 2015
- Completion date
- August 26, 2016
- Enrollment
- 490 (actual)
- Sites
- 56
Conditions
As the registry lists them; a condition with its own page is linked.